1027398-46-4

Upstream product

• 289891-94-7 2-(allyloxy)-1-fluoro-4-(trifluoromethyl)benzene 
• 289891-93-6 7-fluoro-4-(trifluoromethyl)benzofuran-2-carbaldehyde 
• 289891-95-8 2-allyl-6-fluoro-3-(trifluoromethyl)phenol 
• 289891-97-0 6-fluoro-2-(oxiran-2-ylmethyl)-3-(trifluoromethyl)phenol 
• 289891-99-2 (7-fluoro-4-(trifluoromethyl)benzofuran-2-yl)methanol 
• 289891-98-1 (7-fluoro-4-(trifluoromethyl)-2,3-dihydrobenzofuran-2-yl)methanol 
• 289892-00-8 (3-bromo-7-fluoro-4-(trifluoromethyl)-2,3-dihydrobenzofuran-2-yl)methyl acetate 
• 289891-96-9 (7-fluoro-4-(trifluoromethyl)-2,3-dihydrobenzofuran-2-yl)methyl acetate 
• 141483-15-0 2-fluoro-5-trifluoromethylphenol 
• 1026821-73-7 4-[4-(7-fluoro-4-trifluoromethyl-benzofuran-2-yl)-4-oxo-butyryl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

Discovery of novel and potent retinoic acid receptor α agonists: Syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives

In the course of our studies on retinoic acid receptor (RAR) agonists, we have designed and synthesized a series of benzofuran and benzothiophene derivatives. Some of these compounds (1a,b,e,f,j) markedly inhibited LPS- induced B-lymphocyte proliferation and exerted RARα selectivity. One of them, 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoic acid (1b), when orally administered significantly inhibited mouse antibody production and delayed type hypersensitivity (DTH) responses from a dose of 0.1 mg/kg.